

10/02/88



Vol. 14 No. 38

September 30, 1988

©Copyright 1988 The Cancer Letter Inc.  
Subscription: \$175 year North America,  
\$190 year elsewhere

P.O. Box 2370 Reston, Virginia 22090 Telephone 703-620-4646

### Wyngaarden Opens Up Search For NCI Director, Invites Recommendations From Cancer Groups

The search for a new NCI director, which may in reality be limited to a handfull of names known only to White House insiders, has apparently been thrown wide open. NIH Director  
(Continued to page 2)

In Brief

### McIntyre New AACI President, Salmon President Elect; Hubbard NCI AD; Ungerleider CIB Chief

ROSS MCINTYRE, director of the Norris Cotton Cancer Center at Dartmouth, is the new president of the Assn. of American Cancer Institutes. Sydney Salmon, director of the Arizona Cancer Center, has been elected vice president and president elect. Immediate Past President Alan Sartorelli is chairman of the board. New directors are Jerome Yates, associate director for clinical affairs at Roswell Park Memorial Institute; Shirley Lasky, director of the Illinois Cancer Council; and William Fishman, director of the La Jolla Cancer Research Foundation. Edwin Mirand, who has been secretary treasurer since 1967, was reelected to that position. . . .

SUSAN HUBBARD, director of NCI's International Cancer Information Center, was promoted to NCI associate director with the separation of ICIC from the Office of International Affairs. ICIC includes PDQ, "Journal of NCI," Cancergrams and the International Cancer Research Data Bank, among other information services. . . . RICHARD UNGERLEIDER has been named acting chief of the Clinical Investigations Branch of NCI's Cancer Therapy Evaluation Program. The branch oversees the clinical cooperative groups and thus has responsibility for most of the Div. of Cancer Treatment's extramural clinical trials. Michael Friedman, former branch chief, is now acting CTEP director (The Cancer Letter, Sept. 23), with the impending departure of Robert Wittes. . . .

CORRECTIONS: U.S. Bioscience, in its marketing agreement with Eastman Pharmaceuticals for the radio and chemo protective agents WR 2721, WR 151327 and a third generation of anticancer agents (Cancer Economics, Sept. 2), retained rights to those agents for North America and Japan. Also, the phone number to contact regarding the meeting, "Toward the Year 2000 IV" at Fox Chase Cancer Center was incorrect (Meetings, Aug. 29). The correct number is 215/728-2781. . .

AMERICAN ASSN. for Cancer Research headquarters has been moved to 530 Walnut Ave., 10th Floor, Philadelphia, PA 19106, phone 215/440-9300.

### New Cancer Awards

Worth \$1 Million

A Year Announced

. . . Page 2

### Organ Systems

Support Contract

To Cost More

Than OSCC Grant

. . . Page 3

### Reauthorization

Still Held Up

. . . Page 5

### Watson To Head

Genome Research

. . . Page 6

### Three Nurse

Awards Made

In Self Care

. . . Page 7

### NCI Advisory Group,

Other Cancer Meetings

. . . Page 7

## Wyngaarden Opens Up Search For New NCI Director, Seeks Recommendations

(Continued from page 1)

James Wyngaarden told the National Cancer Advisory Board Monday that invitations had been sent to more than 1,000 organizations and individuals to submit their recommendations.

"If you know some who did not [receive the letter asking for recommendations], let them know they should not be inhibited, and should go ahead and submit their recommendations," Wyngaarden said.

His comments wrapped up a couple of weeks of mixed signals and confusion among some of the professional societies and their staff members. Some had been informally contacted by members of, or advisors to, a search committee which included Wyngaarden, Assistant Secretary for Health Robert Windom, and various nongovernment advisors, most prominent of whom was Benno Schmidt, first chairman of the President's Cancer Panel.

Then, while in the process of determining first if they wanted to make any recommendations and second who they would be, they heard that the Wyngaarden committee had been disbanded.

"We don't know what they want," one professional society staff member said Monday prior to the NCAB meeting.

Wyngaarden cleared that up. He said the committee had had two meetings, including one in New York with its outside advisors. He indicated the White House had approved the committee and had asked that it submit its list by Oct. 1.

"We told them that was too soon," Wyngaarden said. The deadline now is Nov. 10, with President Reagan still planning to make the appointment regardless of who wins the election.

Presumably, the White House would clear the appointment with George Bush, should he win. But if Michael Dukakis is the winner, it would seem prudent for Reagan's selection to find out if Dukakis would retain him/her, since the NCI director serves at the pleasure of the President. Reagan retained Vincent DeVita, Jimmy Carter's appointee, but not until an ill advised effort by some Republican senators to force him out collapsed under protests from an outraged scientific community.

Wyngaarden said that the list in hand now is "large," and it includes a number of NIH intramural staff. White House sources have told *The Cancer Letter* that the appointment would

come from outside NIH, although there are a number of highly qualified staff members who would be interested.

Sources also insisted this week that the White House has its own list of prospects, which may or may not include some of those on Wyngaarden's list.

Wyngaarden said that letters inviting recommendations have been sent to deans of medical schools and schools of public health, and to presidents "of all the cancer organizations we could identify."

Those included the American Assn. for Cancer Research, American Society of Clinical Oncology and the Assn. of American Cancer Institutes, among others.

Apparently, it did not include the American Cancer Society. An ACS staff member said he did not know of a letter from Wyngaarden, "and I'm not sure we would want to make a recommendation anyway. If asked, we might comment on an individual's qualifications."

Recommendations may be sent to Dr. James B. Wyngaarden, Director, National Institutes of Health, Building 1 Rm 124, Bethesda, MD 20892.

DeVita was present at Monday's NCAB meeting, his first in eight years not as the NCI director, and his first ever as a private citizen. He was there to accept an award from the Board, commending him for his service to NCI and the National Cancer Program.

He left before Wyngaarden, with whom he has clashed in sometimes bitter behind the scenes struggles, praised him for his "enormous contributions" to NIH and cancer research.

Wyngaarden thanked Alan Rabson for serving as acting director.

DeVita is taking a sabbatical and will not start work at his new job, as physician in chief of Memorial Hospital, until after the first of the year.

DeVita had just returned from Trento, Italy, where he accepted the Pezcoller Foundation Award.

## New Cancer Awards Totaling \$1 million Announced By Milken Foundation

A new series of awards for distinguished clinical and basic scientists in the field of cancer has been announced by the Milken Family Medical Foundation of Los Angeles in cooperation with Salick Health Care Inc. of Beverly Hills.

The Foundation said that it will begin this

year "to give over \$1 million on an annual basis to individuals involved in eradicating this dreaded disease."

The awards this year will include two of \$250,000 each, and six of \$50,000 each. A spokesman said that additional awards may be added in subsequent years, pushing the total over \$1 million.

The awards are as follows:

--A Distinguished Clinician Award of \$250,000 will be given to a clinical investigator whose work had led to a major advance in the treatment of patients with cancer.

--A Distinguished Investigator in Basic Sciences Award of \$250,000 will be given to a scientist whose research has led to a major advance in the treatment or diagnosis of cancer.

--Six awards of \$50,000 each will be made to outstanding investigators in both clinical and basic sciences whose work may lead to important advances in the treatment or diagnosis of cancer.

Candidates may be nominated from any country, from any of the clinical oncology disciplines, and from any of the basic science disciplines, including but not limited to, the Foundation said, molecular biology, molecular genetics, pharmacology, biochemistry, immunology, epidemiology and cell biology.

The Milken Family Medical Foundation has in the past made major awards in the fields of education and epilepsy. In the past eight years, the family, which includes financier Michael Milken, has lost a father, stepfather, mother in law, several aunts and a number of cousins to cancer, leading the family to make a major commitment to cancer research.

"We are only several important breakthroughs away from finding cures for most cancers, and it is within the realm of possibility that within 20 years, cancer as we know it will go the way of polio, smallpox and measles," the Foundation said.

"It is with this in mind that the Milken family wishes to stimulate a concerted effort in the field of cancer research and treatment. We believe that ultimately people will make a difference. People are our greatest asset. All the great discoveries through the ages have come from people who have had the tenacity, dedication and the vision in the field of research. But research often takes years, and many first class researchers eventually go the way of private practice.

"Our goal at the Milken Foundation is to enable the finest minds available in cancer

research and therapy to continue their work unfettered by monetary considerations, as well as to promote new, up and coming researchers who are deemed by their peers to have significant potential in the years to come."

The selections will be made by an Awards Committee chaired by Gerald Rosen, scientific director of Salick Health Care and director of Salick's Cedars Sinai Comprehensive Cancer Center in Los Angeles. Other members of the committee are Bruce Chabner, director of NCI's Div. of Cancer Treatment; Alex Fefer, Fred Hutchinson Cancer Center; Emil Frei, director of the Dana-Farber Cancer Institute; David Golde, UCLA Center for Health Sciences; Steven Rosenberg, chief of surgery at NCI; Philip Schein, president of U.S. Bioscience; and Salick.

Some of the committee members may be among those nominated for the awards. If so and they wish to be considered, they would resign from the committee.

Deadline for receipt of nominations for the 1988 awards is Oct. 21. They should include the individual's affiliation, a brief biographical sketch, summary of major accomplishments, and the reason for selection. Indicate the recommended category of award. Nominations should be sent to the Milken Family Medical Foundation, Annual Cancer Awards, 270 N. Canon Dr. Suite 1197, Beverly Hills, CA 90210.

Rosen may be contacted by phone at 213/855-3030.

*A form for nominations will be included with next week's issue of The Cancer Letter.*

## **Organ Systems Support Contract To Cost More Than OSCC Grant**

NCI's Organ Systems Program, revamped once again and this time heading for elimination of the external coordinating center as determined earlier this year by the National Cancer Advisory Board, seems to have come full circle.

One of the original reasons given by NCI justifying the request not to recompute the Organ Systems Coordinating Center grant held by Roswell Park Memorial Institute was that it would "save money" by bringing it in house.

NCI backed away from that position when it was pointed out that most of the \$800-900,000 a year in the grant supported the seven working groups, their travel, workshops, newsletters and other communication/information modalities. Some NCAB members still

thought that somehow, an inhouse operation would be more effective or more economical. When the Board voted to disperse the portfolio of organ systems grants among the program divisions, in effect making it an institute wide effort, it also voted not to recompute the coordinating center grant.

Staff had admitted then that it did not have the positions to do the support work inhouse, and that it would have to contract for most, if not all, of the work carried out by the coordinating center, under the director of James Karr, the principal investigator.

The new, institute wide program, is now in place and appears to be working well. NCI program directors are enthusiastic about it and work with organ systems staff in the workshops and development of new research concepts. Those concepts quite likely will have a warmer reception from the divisional boards of scientific counselors, although those generated under Karr's guidance fared fairly well. The NCI Organ Systems Committee, chaired by Brian Kimes of the Div. of Cancer Biology & Diagnosis, has handled the transition smoothly and has developed some long range plans.

But the replacement of the coordinating center grant with a contract left some observers still wondering what that will accomplish, especially after presentation of the concept for the contract to the NCAB Organ Systems Committee this week.

Staff estimated that the contract will cost \$940,000 total in its first year, about \$120,000 more than the grant is costing in its final year of operation, which will end next July 31.

David Longfellow, member of the NCI Organ Systems Committee from the Div. of Cancer Etiology, presented the concept. He noted that from \$450,000 to \$500,000 is required for travel during the year. He also acknowledged that Roswell Park paid all of Karr's salary, none of which was charged to the grant; and that two health science administrators working under the grant had most of their salaries paid by Roswell Park (80 percent in one case, 40 percent in the other) "while we get 80 percent of their time."

The work being done by Karr and his health science administrators (primarily with the working groups) will be done by NCI staff under Andrew Chiarodo and including William Straile and Elizabeth Anderson. Under the former system, they managed grant portfolios; now they will work with the working groups. "We expect them to be involved in scientific

decisions, as our experts in organ systems," Kimes said. "They will not be just executive secretaries."

Under any reasonable accounting system, their salaries would be charged against the Organ Systems Program, as it was in the past. But now, at least part of the salaries of Kimes, Longfellow and other members of the NCI committee--Michael Friedman of the Div. of Cancer Treatment and James Callahan of the Div. of Cancer Prevention & Control--also should be charged against the program.

The concept approved by the NCAB committee will be developed into an RFP and competed, probably as a small business set aside. It will be a four year award, with an estimated total cost over that time of \$3,760,000, as a task order agreement. The concept statement follows:

The purpose of this new contract initiative will be to obtain services which will support the activities of the OSP. Services will include conference and workshop management, and technical support and report documentation.

The OSP seeks to establish advisory networks which respond rapidly, flexibly and comprehensively to new trends and opportunities. The working groups analyze trends, program plans, priorities, and identify opportunities and needs in research, training, and research resources. NCI staff reports keep the working groups apprised of NCI activities in the relevant organ systems areas. The working groups address the entire range of cancer activities, i.e., biology, etiology, detection, diagnosis, treatment, prevention, and control of organ system cancers. This enables them to identify areas that are inadequately addressed, exploitable opportunities that may benefit from interdisciplinary approaches, and resources needed to address these opportunities.

The working groups meet as needed to advise NCI. As potential new areas for research initiatives are identified, they are often explored in greater depth through subcommittees which include ad hoc members who provide the additional scientific expertise. NCI staff, working closely with the working groups and their subcommittees, develop background papers which document the need, objectives, rationale and justification for working group recommendations. These form the basis for NCI staff to develop appropriate program initiatives, e.g., concepts for possible issuance as RFAs, RFPs, or program announcements after review by boards of scientific counselors. In conjunction with program staff, working groups also develop workshops designed to achieve specific objectives and they provide advice and recommendations on a broader scale to identify short term and long term objectives in relation to the Year 2000 goals.

Currently, the Organ Systems Program manages seven working groups which address cancers of the breast, central nervous system, large bowel, pancreas, prostate, upper aerodigestive tract, and urinary bladder. Other organ systems may be addressed in the future as needed. The broad scope of the program encompasses all program divisions of NCI. Large numbers of working group meetings, subcommittee meetings, and workshops are involved. Working group activities and recommendations must be implemented in an efficient, rapid and

timely manner. Thus, there is a need for logistical support to the OSP in managing the working groups and in providing technical support and report documentation.

The contractor shall provide assistance throughout the program in a variety of activities. The major tasks consist of Logistical support for working group meetings and workshops, and providing assistance to NCI staff in preparing background papers and other reported related to these meetings. Specifically, the contractor shall perform but not be limited necessarily to the following activities:

1. Assist in the selection of and arrange for suitable conference/meeting facilities locally.
2. Provide a reservation service for accommodations and travel arrangements for the attendees.
3. Provide reimbursement for participant expenses.
4. Prepare, reproduce and distribute all necessary advance materials.
5. Assist in designing and preparing necessary background materials and reports and distribute as necessary.
6. Provide onsite conference service functions.
7. Prepare, edit and reproduce minutes.
8. Prepare, reproduce and distribute post conference materials.
9. Provide technical, scientific and editorial support for meeting summaries, working group reports and publications and annual reports.
10. Collect and summarize scientific information on the current status of research for organ systems areas of specific interest.
11. Review and edit pertinent technical information.
12. Provide graphic support for presentations.
13. Provide storage space for the maintenance and dissemination of resource documents and publications.

"This may be a simple question," NCAB committee member Walter Lawrence commented. "What did the Organ Systems Coordinating Center do that this contract won't?"

"They brought scientific expertise to the working group meetings," Longfellow said. Kimes added that the current organ systems staff, which no longer has grant portfolio management, now will bring their scientific expertise to the meetings."

"In essence, this will cost more," Lawrence said.

"The overhead will cost more," Longfellow agreed.

## **Reauthorization Still Held Up; Status Of Other Legislative Issues Reported**

As the 100th Congress races toward adjournment (now expected no later than Oct. 15), reauthorization of biomedical research, including renewal of the National Cancer Act, remains on hold.

The Senate has passed a reauthorization bill which includes the Cancer Act with nearly all of the changes sought by the National Cancer Advisory Board and other cancer program

advocates. No similar bill has yet been introduced in the House.

The House has passed a bill creating a new National Institute for Deafness; the Senate has not.

The Senate has asked the House to go to conference with it on the two measures, with the understanding that they would be combined, the Senate accepting the new institute and the House going along with the Senate's reauthorization package. But the House has balked, for what reason is not clear. Chairman John Dingell of the House Energy & Commerce Committee (parent of the Health & Environment Subcommittee chaired by Henry Waxman) reportedly has some problems with one or the other of the two measures.

If no reauthorization bill is passed before adjournment, the legislative process will have to start all over again with the new Congress in January. In the meantime, the various authorizations expire Sept. 30. That means that NIH will entirely be operating under the general provisions of the Public Health Service Act. NCI's special authorities technically would no longer exist, but no one expects the Administration to dismantle them. In fact, there have been extended periods in the past between reauthorizations, without too much disruption.

If the hiatus were to continue through next year, critics of the National Cancer Act can be expected to take advantage of it, and NCI's special authorities would start to erode.

In the meantime, there are other legislative issues affecting NCI and the cancer program:

<> The Senate Appropriations Committee has requested that NIH contract with the Institute of Medicine to undertake a study of the present state of the Cancer Centers Program. The study is to include a review of the funding and organizational needs required to fulfill the role established for cancer centers by the National Cancer Act. The Senate expects IOM to consult with the Assn. of American Cancer Institutes during the study.

AACI in fact instigated the study following discussions last summer with Capitol Hill staff members. AACI was not happy with allocation of funds to the centers program in FY 1988, contending that about \$15 million of \$118 million intended for centers by Congress had been moved to other programs by NCI.

<> The Senate Appropriations Committee acknowledged in its report on the 1989 appropriations bill that third party reimbursement for some forms of cancer treatment

can be difficult, and therefore asked that NCI report prior to next year's hearings on the remedies that might be available and their costs.

<> Concern over the need to maximize cancer prevention and control efforts stimulated the Senate Appropriations Committee to request NCI to prepare a report outlining the best professional judgment as to what funding and programs are needed in this area.

<> The committee asked the National Center for Nursing Research to submit a report describing specific initiatives and projects which have been supported in the nursing oncology area.

<> PL 100-418 authorizes an \$85 million National Science Foundation Academic Research Facilities Modernization Program. The new law provides for merit based matching (50-50) grants to institutions of higher education, independent nonprofit research institutions and research museums for repair, renovation or replacement of obsolete laboratories and other facilities.

<> Nutrition monitoring. An amended version of S. 1081, the National Nutrition Monitoring and Related Research Act, passed the Senate and subsequently was sent to the House where it was referred to the House Agriculture Committee and the Committee on Science, Space & Technology.

The purpose of the Senate bill is to enhance the government's ability to collect and disseminate information concerning nutritional quality of the nation's food supply and to coordinate national data gathering programs and dietary guidance. Of particular interest is the title requiring the secretaries of HHS and DOA to be responsible for publishing every five years dietary guidelines for Americans on the basis of current scientific and medical knowledge. The bill also would require a period of public comment prior to the issuance of dietary guidance by any federal agency subject to review by both secretaries.

<> The House passed HR 5150, the Clinical Laboratory Improvements Amendments of 1988. This bill would require a uniform set of standards for all labs, including physician office labs, based on the complexity of tests performed.

<> A provision of the recently passed Medicare Catastrophic Coverage Act of 1988 mandates the HHS secretary to conduct a study of the possibility of including drugs and biologics not yet approved or licensed by FDA as covered by outpatient drugs under the

Medicare program. The report is due Jan. 1, 1990, and must be based on a study conducted in consultation with an advisory board of consumers, experts in the fields of cancer chemotherapy and immunosuppressive therapy, representatives of pharmaceutical manufacturers, and any other individuals selected by the secretary. Because it is likely that Group C treatment IND drugs (those with proven effectiveness against one or more forms of cancer but which have not been approved for marketing by FDA) could be included in this study, NCI has asked that it participate in the design and oversight of the study and identification of candidates for the advisory board.

## **Watson To Head Genome Research; New Group To Promote Collaboration**

James Watson, Nobel Laureate and director of Cold Spring Harbor Laboratory, has accepted appointment as NIH associate director for human genome research.

Watson plans to spend one day a week at NIH and will continue as director at Cold Spring Harbor.

Meanwhile, a new organization has been formed to promote international collaboration on mapping and sequencing the human genome --Human Genome Organization. Victor McKusick, director of medical genetics at Johns Hopkins, has been elected president.

"The mapping of the human genome is one of the major scientific undertakings of the remainder of the 20th century," McKusick said. "Knowledge gained from the project will have great benefits for human health and well being."

McKusick said that a map of the human genome could guide scientists to more effective methods of diagnosing and treating hundreds of inherited disorders. The chromosomal location is now known for about 1,500 of the 50,000 to 100,000 genes on the human genome.

HUGO plans to:

--Help coordinate research on the human genome and provide international training programs on relevant methodology.

--Arrange for the exchange of data, samples and technology relevant to research.

--Foster parallel studies in model organisms, such as the mouse, and coordinate that research with the human genome project.

--Provide public debate and develop guidelines on ethical, social, legal and commercial implications of the human genome project.



The organization also intends to develop plans for regional centers for large scale mapping and sequencing. The centers will coordinate major resources, including databases, collections of DNA clones, cell lines and other biological reagents. HUGO's experts will offer advice to governmental and non-governmental agencies on the support of genome research.

Other officers of HUGO are:

--Vice presidents Walter Bodmer of the Imperial Cancer Research Fund Laboratory, London; Jean Dausset of CEPH in Paris; and Kenichi Matsubara of Osaka Univ., Japan.

--Secretary John Tooze of EMBO, Heidelberg, and Treasurer Walter Gilbert of Harvard Univ.

--Executive committee members Charles Cantor, Columbia Univ.; Malcolm Ferguson-Smith, Cambridge Univ., UK; Leroy Hood, California Institute of Technology; Lennart Philipson, EMBL, Heidelberg; and Frank Ruddle, Yale Univ.

HUGO's 42 member council has five Nobel Laureates, including Watson, Dausset, Gilbert, Renato Dulbecco and Francois Jacob.

## Three Awards Made In Cancer Nursing Interventions To Promote Self Care

NCI's Community Oncology & Rehabilitation Branch in the Div. of Cancer Prevention & Control has awarded three grants in response to its RFA for cancer nursing interventions to promote patient self care.

The three year awards went to:

<> Marilyn Dodd, RN, PhD, associate professor at the Univ. of California (San Francisco) School of Nursing, Dept. of Physiological Nursing. The project is titled, "Self Care Interventions to Decrease Chemotherapy Morbidity," with first year direct costs of \$166,747.

<> Darlene Mood, PhD, associate professor and chair of nursing systems at Wayne State Univ. The project is titled, "Promoting Patient Self Care in Head and Neck Cancer," with first year direct costs of \$95,351.

<> Lillian Nail, RN, PhD, assistant professor of nursing at Univ. of Rochester School of Nursing. The project is titled, "Influencing Self Care: Focused Review and Followup," with first year direct costs of \$96,955.

Anne Bavier, program director for nursing research, said that there are no plans at present to reissue the RFA. "However, we encourage investigators to pursue this line of

inquiry in the investigator initiated grant application pool."

Bavier may be contacted at NCI, DCPC, Blair Bldg Rm 7A05, Bethesda, MD 20892, phone 301/427-8708.

The Third Annual Oncology Nursing Conference at NIH Oct. 7 will be devoted to safe handling of antineoplastic agents. It will start at 8:30 a.m., in the Clinical Center, Masur Auditorium. There is no registration fee, but those planning to attend should contact Caryn Steakley, Cancer Nursing Dept., Clinical Center Rm 7D37, National Institutes of Health, Bethesda, MD 20892.

## NCI Advisory Group, Other Cancer Meetings For Oct., Nov., Future

**Royal Australian College of Radiologists**--Oct. 2-9, Auckland, New Zealand. 39th annual scientific meeting. Contact Dr. G. Foote, Dept. of Radiology, Auckland Hospital, Private Bag, Auckland, N.Z.

**Symposium on Variability in Pharmacokinetics and Drug Response**--Oct. 3-5, Gothenburg, Sweden. Contact Symposium, Swedish Academy of Pharmaceutical Sciences, PO Box 1136, 111 81 Stockholm, Sweden.

**Epstein-Barr Virus and Associated Malignant Diseases**--Oct. 3-7, Rome. 3rd international symposium. Contact Dr. Alberto Faggioni, Dipartimento de Medicina Sperimentale, Viale Regina Elena 324, 00161, Rome, Italy; or Dr. D.V. Ablashi, EBV Assn., PO Box 895, Olney, MD 20832.

**Cellular and Molecular Biology of Human Carcinogenesis**--Oct. 5-6, McArdle Research Laboratory, Univ. of Wisconsin (Madison). Eleventh annual Bristol-Myers Cancer Research Symposium. Contact Virginia Mintz, 202/785-1471.

**German Society for Laser Medicine**--Oct. 5-8, Vienna. 4th annual meeting. Contact Dr. A. Tuchmann, c/o Wiener Medizinische Akademie, Alser Strasse 4, A-1090 Vienna, Austria.

**Div. of Cancer Prevention & Control Board of Scientific Counselors**--Oct. 6-7, NIH Bldg 1 Wilson Hall, 8:30 p.m. both days.

**Div. of Cancer Treatment Board of Scientific Counselors**--Oct. 6-7, NIH Bldg 31 Rm 10, open 9 a.m. Oct. 6, 8:30 a.m. Oct. 7.

**Harvard Postgraduate Course on Urologic Cancer**--Oct. 6-8, Boston. Contact Dr. Jerome Richie, phone 617/732-6598.

**Cancer Program Planning Workshop**--Oct. 6-7, Mariner's Inn, Hilton Head Island, SC. Contact Nancy Reid, Cancer CarePoint, 2394 Mt. Vernon Rd., Suite 200, Atlanta, GA 30338, phone 404/399-1812.

**Safe Handling of Antineoplastic Agents**--Oct. 7, NIH Clinical Center, Masur Auditorium. Latest guidelines in the safe handling of antineoplastics as it applies to health care workers. Third annual Oncology Nursing Conference, sponsored by the NIH Cancer Nursing Service. Contact Cancer Nursing Dept., Clinical Center Rm 7D37, NIH, Bethesda, MD 20892.

**American Society for Therapeutic Radiology and Oncology**--Oct. 9-14, New Orleans. 30th annual meeting. Contact ASTRO, 1891 Preston White Dr., Reston, VA 22091, phone 703/648-8900.

**Development and Differentiation: Modern Approaches to Classical Problems**--Oct. 11-14, Houston. 41st annual symposium on fundamental cancer research. Contact Office of Conference Services, UT M.D. Anderson

Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, phone 713/792-2222.

**Second International Conference on Anticancer Research**--Oct. 11-15, Porto-Carras, Halkidiki, Greece. Contact Dr. John Delinassios, Anticancer Research, 5, Argyropoulou Str., Kato Patissia, Athens 11145, Greece.

**American Society of Human Genetics**--Oct. 12-16, New Orleans. Annual meeting. Contact Margaret Gardiner, ASHG, 15501-B Monona Dr., Derwood, MD 20855, phone 301/424-4120.

**Control of Cell Proliferation and Cancer**--Oct. 13-14, Royal Sonesta Hotel, Cambridge, MA. 1988 symposium. Contact Office of Continuing Education, Tufts Univ. School of Medicine, 136 Harrison Ave., Box 36, Boston, MA 02111, phone 617/956-6579.

**Biometry and Epidemiology Contract Review Committee**--Oct. 13-14, Bethesda Marriott, open Oct. 13 9-10 a.m.

**Nonmelanoma Skin Cancer**--Oct. 15, Cleveland. Symposium for physicians, with CME credit. Contact Barbara Guy, Assistant to the Director, Ireland Cancer Center, Lowman Bldg 211, University Hospitals of Cleveland, 2074 Abington Rd., Cleveland, OH 44106, phone 216/844-7856.

**Toward 2000 IV, Oncology Today**--Oct. 20-21, Fox Chase Cancer Center, Philadelphia. Contact Mrs. Janet Dooley, Conference Coordinator, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111, phone 215/728-2781.

**DNA Probes: Market Challenges and Opportunities**--Oct. 25, Marriott Hotel, San Diego. Executive conference. Contact Communitech Market Intelligence, PO Box 67, Yorktown Heights, NY 10598, phone 914/245-7764.

**Div. of Cancer Etiology Board of Scientific Counselors**--Oct. 27-28, NIH Bldg 31 Rm 10, open Oct. 27 1 p.m.-adjournment and Oct. 28 9 a.m.-adjournment.

**European Society for Medical Oncology**--Oct. 30-Nov. 1, Lugano, Switzerland. 13th congress. Contact F. Cavalli M.D., Div. of Oncology, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.

**Joint Congresses: XXIX Brazilian/XXI PanAmerican Otolaryngology and Head and Neck Surgery**--Oct. 30-Nov. 4, Salvador, Bahia, Brazil. Contact Dr. Severino Cortizo, Rua Humberto de Campos 11-902, Salvador 40150, Bahia, Brazil.

**Frontiers for Therapeutic Advance**--Oct. 31, Princeton. 50th anniversary symposium for the Squibb Institute for Medical Research. Contact R.H. Jones, phone 609/921-4265.

**Bladder Cancer Symposium**--Nov. 2-4, Cairo. Contact Symposium Secretariat, Dr. Nazli Gad El Mawla, National Cancer Institute, Cairo, Egypt.

**Optimizing Management of Primary Bone Tumors**--Nov. 2-5, Houston. 32nd annual clinical conference, an international symposium emphasizing the multidisciplinary approach. Contact Office of Conference Services, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, phone 713/792-2222.

**Progress in Regional Cancer Therapy**--Nov. 3-5, Vienna. Contact Brigitte Schick, 1 Chir. Univ.-Klinik, Alser-Str. 4, 1090 Vienna, Austria.

**12th Annual Cancer Symposium and 8th Annual Cancer Symposium for Nurses**--Nov. 7-9, Sheraton Harbor Island Hotel East, San Diego. Sponsored by Scripps Memorial Hospital Cancer Center. Contact Nomi Feldman, Conference Coordinator, 3770 Tansy St., San Diego, CA 92121, phone 619/453-6222.

**Update on Cancer of the Head and Neck**--Nov. 11-12, Cleveland. Contact Barbara Guy, Assistant to the

Director, Ireland Cancer Center, Lowman Bldg-211, University Hospitals of Cleveland, 2074 Abington Rd., Cleveland, OH 44106, phone 216/844-7856.

**Institutional Review Boards and Clinical Trials: Protection and Progress in Biomedical Research**--Nov. 11, New York Univ. Medical Center. NIH and FDA regional conference on the protection of human subjects. Phone 212/340-6697.

**Death of a Parent: Impact on School Age Children**--Nov. 15, Calvary Hospital, Bronx, NY. Contact Sr. Patricia Sheridan, phone 212/518-2259.

**Franco-Egyptian Cancer Conference**--Nov. 15, Cairo. Reports on breast cancer, pediatric lymphoma, virology, and cytokinetic studies. Contact Dean's Office, National Cancer Institute, Kasr El-Aini Str., Fom-El-Khalig, Cairo, Egypt.

**Innovative Cancer Chemotherapy for Tomorrow**--Nov. 16-18, Sheraton Centre Hotel, New York. Chemotherapy Foundation Symposium V111. Will include discussion on use of tamoxifen in prevention of breast cancer. Contact Jaclyn Silverman, Div. of Medical Oncology, Box 1178, Mount Sinai School of Medicine, One Gustave L. Levy Pl., New York 10029, phone 212/241-6772.

**Monoclonal Antibodies and Breast Cancer**--Nov. 17-18, San Francisco Hilton & Tower. Third international workshop. Contact Kelly Travers, John Muir Cancer & Aging Research Institute, 2055 N. Broadway, Walnut Creek, CA 94596, phone 415/943-6314.

**Directions in Pediatric Hematology/Oncology Care**--Nov. 17-19, Harbour Island Hotel, Tampa. 12th annual seminar sponsored by the Florida Assn. of Pediatric Tumor Programs. Contact Cindi Butson, Seminar Coordinator, FAPTP, PO Box 13372, University Station, Gainesville, FL 32604, phone 904/375-6848.

**Div. of Cancer Biology & Diagnosis Board of Scientific Counselors**--Nov. 21, NIH Bldg 31 Rm 9, 9 a.m.

**11th Annual San Antonio Breast Cancer Symposium**--Nov. 29-30, San Antonio. Contact Terri Coltman, RN, 4450 Medical Dr., San Antonio, TX 78229.

## FUTURE MEETINGS

**Facing the Challenge: Meeting the Spiritual Needs of Persons with Cancer**--Dec. 1, Calvary Hospital, Bronx, NY. Contact Sr. Patricia Sheridan, phone 212/518-2259.

**Advances in Cancer Treatment Research and Autologous Bone Marrow Transplantation**--March 16-18, 1989, Grand Hyatt Hotel, New York. Focuses on overviews of ABMT's role in cancer treatment, clinical applications of BRMs in cancer therapy, advances in management of most common hematologic and solid tumors, future directions in cancer research. Contact Office of Continuing Medical Education, Albert Einstein College of Medicine/Montefiore Medical Center, 3301 Bainbridge Ave., Bronx, NY 10467, phone 212/920-6674.

**Monoclonal Antibody Immunoconjugates For Cancer**--March 30-April 1, 1989, San Diego Marriott Hotel and Marina. Fourth international conference. Deadline for oral abstract submission is Oct. 21. Three half day topic sessions devoted to isotope, toxin and drug conjugates; a half day session for posters and workshops; and a half day minisymposium on human anti-immunoglobulin response. Contact Cass Jones, Meeting Management, 3770 Tansy St., San Diego, CA 92121.

**5th European Conference on Clinical Oncology**--Sept. 3-7, 1989, South Bank Centre, London. Deadline for abstracts is March 1. Contact Conference Associates ECCO, Congress House, 55 New Cavendish St., London W1M 7RE, UK.

## The Cancer Letter \_ Editor Jerry D. Boyd

Associate Editor Patricia Williams

Published forty-eight times a year by The Cancer Letter, Inc., P.O. Box 2370, Reston, Virginia 22090. Also publisher of The Clinical Cancer Letter. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.